Specialty
Certifications
Medical Oncology
American Board of Internal Medicine
Clinical Focus
Education
Residency, Internal Medicine
Bronx-Lebanon Hospital CenterResidency, Internal Medicine
Harper HospitalFellowship, Medical Oncology
MD Anderson Cancer Center (Univ of Texas)
Biography
Sundar Jagannath, MD, is Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute. Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma — a relatively rare cancer of the bone marrow.
Prior to joining Mount Sinai, Dr. Jagannath served as chief of the multiple myeloma and transplant program at St. Vincent’s Hospital Comprehensive Cancer Center from 1998 until the hospital closed
in April 2010. The transplant program, with stored stem cells of more than 300 patients, and the myeloma program with ongoing clinical trials, have been integrated into The Tisch Cancer Institute.
Mount Sinai’s Multiple Myeloma Program provides clinical care to a large patient population, including the transfer of more than 800 patients who had been receiving care at St. Vincent’s.
Dr. Jagannath has published more than 180 peer-reviewed articles in top publications, including the New England Journal of Medicine, Blood, the Journal of Clinical Oncology and Cancer. He has presented more than 150 abstracts and authored nearly 30 book chapters.
Clinical Trials
- Multicenter phase I/II study on the anti-tumor activity, safety and pharmacology of IPH 2101, a human monoclonal anti KIR, combined with lenalidomide in patients with Multiple Myeloma experiencing a first relapse
- Evaluation of pomalidomide in combination with high dose dexamethasone and oral cyclophosphamide in patients with relapsed and refractory myeloma
- A Phase I/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects with Refractory, Relapsed or Relapsed/Refractory Multiple Myeloma
- Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONYX 0912 in Patients with Hematological Malignancies
- A Phase 2 Biomarker Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
- A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
- A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
- A Phase I/II, Open-label, Multicenter Study of ACY-1215 administered Orally As Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Jagannath during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Onyx Pharmaceuticals, Inc.
Scientific Advisory Board:
- Celgene Corporation; Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited )
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Celgene Corporation; Merck & Co., Inc.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- PharmaMar (Zeltia Group)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave L. Levy Place
Box 1185
New York, NY 10029
1470 Madison Avenue
New York, NY 10029
